RAJA SIVAMANI
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- ROCKLIN, CA
- NPI
- 1811197478
- Received
- $2,075,267 in 1,776 records, 2019 to 2025 ($1,880,749 general, $194,518 research)
- As principal investigator
- $9,969,180 of research payments to others in 763 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 561 | $663,153 |
| 2025 | Research payment | 2 | $57,501 |
| 2024 | General payment | 520 | $584,800 |
| 2024 | Research payment | 11 | $129,213 |
| 2023 | General payment | 398 | $432,306 |
| 2023 | Research payment | 1 | $324 |
| 2022 | General payment | 165 | $137,702 |
| 2021 | General payment | 51 | $17,246 |
| 2020 | General payment | 12 | $44,256 |
| 2020 | Research payment | 2 | $2,948 |
| 2019 | General payment | 30 | $1,283 |
| 2019 | Research payment | 23 | $4,530 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 374 | $1,393,802 |
| Consulting Fee | 72 | $249,701 |
| Travel and Lodging | 547 | $198,995 |
| Research payment | 39 | $194,518 |
| Food and Beverage | 733 | $34,915 |
| Honoraria | 4 | $3,105 |
| Education | 7 | $228 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | Incyte Corporation | $7,335 | Consulting Fee | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-23 | Incyte Corporation | $4,890 | Consulting Fee | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-23 | LEO Pharma Inc. | $4,073 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-12-23 | Incyte Corporation | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-22 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-22 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-19 | Eli Lilly and Company | $35 | Food and Beverage | Cash or cash equivalent | TALTZ Drug, Immunology | 2025 | |
| 2025-12-19 | Eli Lilly and Company | $33 | Food and Beverage | Cash or cash equivalent | TALTZ Drug, Immunology | 2025 | |
| 2025-12-19 | Eli Lilly and Company | $25 | Food and Beverage | Cash or cash equivalent | TALTZ Drug, Immunology | 2025 | |
| 2025-12-19 | Eli Lilly and Company | $24 | Travel and Lodging | Cash or cash equivalent | TALTZ Drug, Immunology | 2025 | |
| 2025-12-18 | Galderma Laboratories, L.P. | $12,600 | Consulting Fee | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-18 | UCB, Inc. | $7,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | LEO Pharma Inc. | $78 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-12-18 | UCB, Inc. | $60 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | UCB, Inc. | $38 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | UCB, Inc. | $8 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | UCB, Inc. | $8 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | UCB, Inc. | $6 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | UCB, Inc. | $5 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Galderma Laboratories, L.P. | $5,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-17 | Galderma Laboratories, L.P. | $5,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-17 | Nielsen BioSciences, Inc. | $3,625 | Consulting Fee | Cash or cash equivalent | Candin Biological, Immunotherapy | 2025 | |
| 2025-12-16 | ABBVIE INC. | $9,100 | Consulting Fee | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-16 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-16 | Incyte Corporation | $121 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-16 | Incyte Corporation | $12 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-12 | Galderma Laboratories, L.P. | $395 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-12 | Galderma Laboratories, L.P. | $248 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-12 | Galderma Laboratories, L.P. | $27 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-12 | Galderma Laboratories, L.P. | $26 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-12 | Galderma Laboratories, L.P. | $20 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-11 | Incyte Corporation | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-11 | Incyte Corporation | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-11 | Incyte Corporation | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-10 | Galderma Laboratories, L.P. | $840 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-10 | Galderma Laboratories, L.P. | $141 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-10 | Galderma Laboratories, L.P. | $30 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-09 | Regeneron Healthcare Solutions, Inc. | $7,259 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-09 | Regeneron Healthcare Solutions, Inc. | $7,259 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-09 | Galderma Laboratories, L.P. | $795 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-09 | Galderma Laboratories, L.P. | $30 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-09 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-12-04 | The Daavlin Distributing Co | $10,000 | Consulting Fee | Cash or cash equivalent | Phothera Phototherapy Devices Device, Phototherapy | 2025 | |
| 2025-12-04 | UCB, Inc. | $5,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | LEO Pharma Inc. | $2,263 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-12-04 | Regeneron Healthcare Solutions, Inc. | $878 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-04 | Incyte Corporation | $83 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-04 | Incyte Corporation | $70 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-04 | Incyte Corporation | $20 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-04 | Incyte Corporation | $19 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $543 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $438 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Regeneron Healthcare Solutions, Inc. | $127 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-03 | Incyte Corporation | $55 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-03 | Incyte Corporation | $17 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-01 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-11-26 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-11-24 | E.R. Squibb & Sons, L.L.C. | $1,085 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-22 | Janssen Biotech, Inc. | $3,825 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-20 | LEO Pharma Inc. | $2,262 | Consulting Fee | Cash or cash equivalent | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-11-20 | UCB, Inc. | $758 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-20 | UCB, Inc. | $576 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-20 | UCB, Inc. | $77 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $71 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-20 | UCB, Inc. | $21 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $19 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $19 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-11-20 | UCB, Inc. | $16 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $16 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $14 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $14 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $14 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $11 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $7 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | UCB, Inc. | $2 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Janssen Biotech, Inc. | $146 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-18 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-11-13 | UCB, Inc. | $7,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-13 | UCB, Inc. | $7,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-13 | UCB, Inc. | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-13 | Incyte Corporation | $1,193 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-13 | UCB, Inc. | $80 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-13 | Incyte Corporation | $9 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-12 | GENZYME CORPORATION | $5,551 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-12 | Incyte Corporation | $1,592 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-12 | Incyte Corporation | $228 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-12 | Incyte Corporation | $43 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-11 | GENZYME CORPORATION | $8,967 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-11 | ABBVIE INC. | $2,600 | Consulting Fee | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-11 | GENZYME CORPORATION | $2,010 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-11 | GENZYME CORPORATION | $261 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-11 | GENZYME CORPORATION | $107 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-10 | ABBVIE INC. | $650 | Consulting Fee | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-10 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-06 | UCB, Inc. | $7,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-06 | UCB, Inc. | $53 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-06 | UCB, Inc. | $33 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-06 | UCB, Inc. | $13 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-05 | Incyte Corporation | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-05 | Incyte Corporation | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-04 | UCB, Inc. | $589 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-04 | Arcutis Biotherapeutics, Inc. | $11 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-03 | Galderma Laboratories, L.P. | $5,600 | Consulting Fee | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-30 | Incyte Corporation | $1,016 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-30 | Incyte Corporation | $120 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-30 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-29 | Incyte Corporation | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-29 | Incyte Corporation | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-29 | Incyte Corporation | $889 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-28 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-27 | Incyte Corporation | $29 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-10-25 | Galderma Laboratories, L.P. | $149 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-25 | Galderma Laboratories, L.P. | $99 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-25 | LEO Pharma Inc. | $35 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-10-25 | Galderma Laboratories, L.P. | $29 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-25 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-24 | Eli Lilly and Company | $4,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TALTZ Drug, Immunology | 2025 | |
| 2025-10-24 | SANOFI US SERVICES INC. | $2,335 | Consulting Fee | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-10-24 | Incyte Corporation | $486 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-24 | Incyte Corporation | $315 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-24 | Incyte Corporation | $181 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-24 | ABBVIE INC. | $92 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-24 | Incyte Corporation | $43 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-24 | Incyte Corporation | $26 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-24 | Incyte Corporation | $22 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-24 | Incyte Corporation | $22 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-24 | Incyte Corporation | $18 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-24 | Incyte Corporation | $18 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-23 | Incyte Corporation | $185 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-23 | UCB, Inc. | $135 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-23 | UCB, Inc. | $135 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-23 | UCB, Inc. | $135 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-23 | Incyte Corporation | $57 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-23 | ABBVIE INC. | $38 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-23 | LEO Pharma Inc. | $30 | Food and Beverage | In-kind items and services | SPEVIGO Biological, DERMATOLOGY | 2025 | |
| 2025-10-23 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-22 | UCB, Inc. | $374 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-22 | UCB, Inc. | $154 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-22 | Incyte Corporation | $112 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-22 | UCB, Inc. | $79 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-22 | UCB, Inc. | $79 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-22 | UCB, Inc. | $79 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-22 | UCB, Inc. | $70 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-22 | UCB, Inc. | $70 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-22 | UCB, Inc. | $70 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-21 | UCB, Inc. | $388 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-21 | UCB, Inc. | $388 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-21 | UCB, Inc. | $78 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-21 | UCB, Inc. | $72 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-20 | UCB, Inc. | $151 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-20 | UCB, Inc. | $151 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-20 | UCB, Inc. | $151 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-20 | UCB, Inc. | $113 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-20 | UCB, Inc. | $113 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-20 | UCB, Inc. | $113 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-20 | Cipher Pharmaceuticals US LLC | $18 | Food and Beverage | Cash or cash equivalent | Natroba Drug, Antiparasitic | 2025 | |
| 2025-10-18 | UCB, Inc. | $59 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-18 | UCB, Inc. | $10 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-18 | UCB, Inc. | $10 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-18 | UCB, Inc. | $10 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-18 | UCB, Inc. | $10 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-18 | UCB, Inc. | $10 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-18 | UCB, Inc. | $10 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-16 | Incyte Corporation | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-16 | Incyte Corporation | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-16 | Incyte Corporation | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-16 | LEO Pharma Inc. | $1,200 | Consulting Fee | Cash or cash equivalent | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-10-16 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-10-16 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-10-15 | UCB, Inc. | $1,190 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-15 | UCB, Inc. | $566 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-15 | UCB, Inc. | $150 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-15 | UCB, Inc. | $84 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-14 | Incyte Corporation | $28 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-10-11 | Janssen Biotech, Inc. | $1,913 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-10 | PFIZER INC. | $885 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-10-09 | Incyte Corporation | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-08 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-08 | Incyte Corporation | $953 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-08 | Incyte Corporation | $131 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-07 | PFIZER INC. | $4,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-10-04 | PFIZER INC. | $1,036 | Travel and Lodging | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2025 | |
| 2025-10-04 | Eli Lilly and Company | $754 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-04 | Eli Lilly and Company | $197 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-04 | Eli Lilly and Company | $197 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-04 | Eli Lilly and Company | $115 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-04 | Eli Lilly and Company | $115 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-04 | UCB, Inc. | $15 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-02 | UCB, Inc. | $7,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-02 | Incyte Corporation | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $906 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $814 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | Incyte Corporation | $120 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-02 | UCB, Inc. | $70 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-02 | UCB, Inc. | $68 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-02 | UCB, Inc. | $65 | Travel and Lodging | Cash or cash equivalent | 2025 |
The latest 200 records of 1,776.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $1,529 | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult | 2025 |
| 2025-12-31 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $3,537 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upad | 2025 |
| 2025-12-31 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $7,771 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-12-25 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR | $2,291 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-12-25 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR | $31,641 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-12-24 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $5,149 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-12-22 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR | $3,782 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-12-19 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR | $8,792 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-12-17 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $5,981 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-12-11 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $1,151 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $4,700 | Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) | 2025 |
| 2025-12-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE AND RESERCH | $1,678 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to | 2025 |
| 2025-12-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $26,833 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-12-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $11,131 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-12-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $36,808 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-12-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $8,391 | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Mod | 2025 |
| 2025-12-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $14,792 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-12-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $15,057 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-12-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $454 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-12-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $18,974 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-12-03 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $5,329 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-11-26 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $10,938 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-11-25 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $1,746 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-11-20 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $11,307 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-11-20 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $2,299 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-11-20 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $4,735 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-11-20 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE AND RESERCH | $515 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to | 2025 |
| 2025-11-19 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $1,054 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-11-13 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $15,020 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-11-13 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $2,562 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-11-05 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $44,453 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-11-05 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $5,007 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-11-05 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $16,251 | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Mod | 2025 |
| 2025-11-05 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $5,138 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-11-05 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $3,093 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-11-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $37,237 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-11-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $12,630 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-11-04 | Eli Lilly and Company | NORCAL MEDICAL RESEARCH INC | $17,182 | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT | 2025 |
| 2025-11-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $13,316 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-11-03 | Eli Lilly and Company | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $6,560 | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEK | 2025 |
| 2025-11-03 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR | $1,710 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-10-31 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR | $1,926 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-10-30 | E.R. Squibb & Sons, L.L.C. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $61 | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinuma | 2025 |
| 2025-10-29 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $1,746 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-10-28 | Novartis Pharmaceuticals Corporation | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $1,143 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety o | 2025 |
| 2025-10-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $12,180 | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolima | 2025 |
| 2025-10-27 | Eli Lilly and Company | NORCAL MEDICAL RESEARCH INC | $6,560 | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEK | 2025 |
| 2025-10-24 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR | $12,440 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-10-22 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $1,584 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-10-20 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR | $13,000 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-10-20 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR | $313 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-10-17 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $712 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-10-15 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $4,587 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-10-15 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $1,132 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-10-15 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $2,469 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-10-15 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $6,455 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-10-09 | Eli Lilly and Company | OSMAN DERMATOLOGY | $3,000 | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITI | 2025 |
| 2025-10-09 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $50,244 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-10-09 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $4,372 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-10-09 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $29,267 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-10-09 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $2,091 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-10-09 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $20,391 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-10-09 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $3,339 | A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Mod | 2025 |
| 2025-10-09 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $9,634 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-10-09 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE AND RESERCH | $1,470 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to | 2025 |
| 2025-10-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $68,502 | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolima | 2025 |
| 2025-10-08 | Novartis Pharmaceuticals Corporation | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $13,404 | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared | 2025 |
| 2025-10-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Northwestern University | $38,638 | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolima | 2025 |
| 2025-10-04 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $62 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-10-01 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $13,248 | Skin Care | 2025 |
| 2025-09-29 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR CH | $2,596 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-09-29 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR CH | $15,414 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-09-29 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR CH | $6,840 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-09-26 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $2,888 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-09-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $18,201 | Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) | 2025 |
| 2025-09-22 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR CH | $698 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-09-19 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $6,218 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-09-12 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $53,231 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-09-11 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $17,610 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-09-11 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $3,160 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-09-11 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $8,656 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-09-11 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $1,404 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-09-11 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $3,952 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-09-11 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE AND RESERCH | $515 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to | 2025 |
| 2025-09-08 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR CH | $18,535 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-09-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $29,426 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-09-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $3,208 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-09-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $45,354 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-09-04 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $4,330 | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil | 2025 |
| 2025-09-03 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $26,408 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-09-03 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE AND RESERCH | $1,470 | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to | 2025 |
| 2025-09-03 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $17,236 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-09-03 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $25,029 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-08-29 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $7,559 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-08-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $1,195 | Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | INTEGRATIVE SKIN SCIENCE AND RESEAR CH | $2,557 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-08-23 | PFIZER INC. | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $7,552 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-08-19 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $1,537 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-08-13 | LEO Pharma AS | INTEGRATIVE SKIN SCIENCE AND RESEARCH | $1,000 | TRACE STUDY: TRALOKINUMAB REAL WORLD CLINICAL USE: AN OBSERVATIONAL COHORT STUDY OF ATOPIC DERMATITIS PATIENTS PRESCRIBE | 2025 |
| 2025-08-07 | ABBVIE INC. | INTEGRATIVE SKIN SCIENCE | $2,122 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rocklin, CA, county Placer County, CA, state California; placed by its city name.
| Measure | Place (city or town) Rocklin, CA | County Placer County, CA | State California |
|---|---|---|---|
| Population B01003 | 73,327 | 419,156 | 39,287,377 |
| Population, 2020 census P1 | 71,601 | 404,739 | 39,538,223 |
| Median age B01002 | 38.4 | 42.5 | 37.9 |
| Under 18 B01001 | 24.6% | 21.8% | 22.0% |
| 65 and over B01001 | 14.3% | 20.5% | 15.7% |
| Households B11001 | 25,951 | 157,954 | 13,548,091 |
| Foreign born B05002 | 14.3% | 12.7% | 27.0% |
| Median household income B19013 | $124,168 | $115,998 | $99,122 |
| Median family income B19113 | $153,926 | $138,699 | $113,346 |
| Per capita income B19301 | $58,054 | $57,862 | $49,513 |
| Poverty rate B17001 | 5.6% | 6.8% | 12.0% |
| Unemployment rate B23025 | 4.5% | 4.8% | 6.6% |
| Civilian labor force B23025 | 36,623 | 206,228 | 20,068,466 |
| Mean commute (minutes) B08013 | 26.1 | 27.4 | 28.7 |
| Bachelor's degree or higher B15003 | 48.0% | 43.2% | 37.1% |
| Housing units B25001 | 26,993 | 179,266 | 14,644,735 |
| Owner-occupied B25003 | 68.3% | 74.8% | 55.9% |
| Renters B25003 | 31.7% | 25.2% | 44.1% |
| Median home value B25077 | $703,400 | $688,100 | $734,700 |
| Median gross rent B25064 | $2,258 | $2,069 | $2,036 |
| White, not Hispanic B03002 | 61.5% | 65.5% | 33.8% |
| Black B03002 | 1.5% | 1.6% | 5.2% |
| Hispanic or Latino B03002 | 16.0% | 15.7% | 40.2% |
| Asian B03002 | 11.3% | 9.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rocklin, CA.
Comments